ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2758

Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study

Carlotta Nannini1, Laura Niccoli2, Emanuele Antonio Maria Cassarà2, Olga Kaloudi2, Stelvio Sestini3 and Fabrizio Cantini2, 1Prato Hospital, Prato, Italy, 2Rheumatology, Prato Hospital, Prato, Italy, 3Radiology, Prato Hospital, Prato, Italy

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: giant cell arteritis and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The efficacy of tocilizumab (TCZ), an anti-IL-6 targeted monoclonal antibody, in patients with refractory GCA has been demonstrated. The purpose of this study was to investigate the persistence of clinical remission after TCZ interruption. We also evaluated the role of acute-phase reactants and 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG –PET) in predicting the relapse and remission, and the occurrence of adverse event (AEs).

Methods:

All refractory GCA patients with involvement of aorta and its thoracic branches received prednisone (PDN) 50 mg/day and intravenous TCZ (TCZiv) 8 mg/Kg/monthly or subcutaneous TCZ (TCZsc) 162 mg/weekly. PDN was tapered and withdrawn at month 2.

At month 6, in patients achieving a stable remission, TCZ was bimonthly tapered as follows: TCZiv 2 mg/Kg, and TCZsc 1 injection every 2, 3 and 4 weeks until month 12. In responders both treatments were interrupted at month 12.

Remission was assessed at months 6, 12, and 18 by the evaluation of GCA symptoms and signs, patient global health assessment by visual analogue scale 1 to 10 (VAS), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP). 18F-FDG –PET was performed at baseline, month 6, and 2 months after TCZ withdrawn. A Standardized Uptake Value normalized for liver uptake (nSUVmax) ≤ 1 was assumed as normal.

Anova test and Person test were used to measure the difference between groups and for correlations respectively.

Results:

15 patients were enrolled, 12 females and 3 males, mean age at diagnosis was 69.8 years (±7.70 SD). Seven patients were treated with TCZiv and 8 patients with TCZsc. After 2 months of TCZ therapy all patients stopped CS, and after 6 months of TCZ treatment all patients were in clinical (VAS mean value 2.01 ±0.76SD), laboratory (ESR 9 mm/1h ±6.66 SD; CRP 0.29 mg/dl ±0.27SD) remission. 11 patients completed the 12-month scheduled follow-up. Of these, 7 maintained the drug-free remission that persisted over a median follow up of 12 months afterward. After 2 months from TCZ discontinuation, in the 7 remitting patients SUVmax and nSUVmax were significantly reduced as compared with baseline, while no differences resulted with 18F-FDG –PET values at month 6. (table 1).

A correlation between nSUVmax and VAS and CRP was found (Pearson 0.9: p 0.0005 and 0.59 p 0.006, respectively).

Four patients reactivated after two months of TCZ discontinuation with median VAS 7,9, median ESR 50, median CRP 1.66. Two patients had stable disease with every other week TCZsc and 2 patients with monthly TCZsc. None of the patients required CS. No AEs were recorded. The remaining 4 patients with incomplete follow up, were in remission with no flares after 8,10, and 12 months of treatment.

Baseline

Month 6

P value

Pre TCZ

After 2 months from TCZ discont.

P value

Month 6

After 2 months of TCZ discont.

P Value

SUVmax mean (±SD)

3.3 (0.36)

2.13 (0.42)

0.0005

3.3 (0.36)

1.9 (0.24)

0.0005

2.13 (0.42)

1.9 (0.24)

0.43

nSUVmax mean (±SD)

1.49 (0.26)

0.85 (0.19)

0.0005

1.49 (0.26)

0.77 (0.15)

0.0005

0.85 (0.19)

0.77 (0.15)

0.76

Conclusion: Drug-free remission maintenance after TCZ discontinuation seems to be a proposable strategy in GCA.


Disclosure: C. Nannini, None; L. Niccoli, None; E. A. M. Cassarà, None; O. Kaloudi, None; S. Sestini, None; F. Cantini, None.

To cite this abstract in AMA style:

Nannini C, Niccoli L, Cassarà EAM, Kaloudi O, Sestini S, Cantini F. Tocilizumab Interruption in Patients with Giant Cell Arteritis Achieving the Clinical Remission: Interim Analysis of an Open-Label, 18-Month, Pilot Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/tocilizumab-interruption-in-patients-with-giant-cell-arteritis-achieving-the-clinical-remission-interim-analysis-of-an-open-label-18-month-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-interruption-in-patients-with-giant-cell-arteritis-achieving-the-clinical-remission-interim-analysis-of-an-open-label-18-month-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology